Literature DB >> 15248165

Relationship between platelet count and bleeding risk in thrombocytopenic patients.

Sherrill J Slichter1.   

Abstract

Platelets are lost from circulation by 2 mechanisms: senescence and random loss. Approximately 7.1 x 10(3) platelets/microL/d are postulated to be randomly used in maintaining vascular integrity. Thus, in clinically stable patients, major bleeding is unusual unless the platelet count is </=5 x 10(3)/microL. Risk factors for bleeding at higher platelet counts are disseminated intravascular coagulation with contributory clotting factor deficiencies, structural lesions with loss of vascular integrity, and refractoriness to platelet transfusions. Several large studies have documented the safety of lowering the prophylactic platelet transfusion trigger from the previously used 20 x 10(3)/microL to 10 x 10(3)/microL. A few studies have even suggested that a 5 x 10(3)/microL trigger is acceptable. Based on these results, the next step of giving just therapeutic platelet transfusions is being evaluated. In a large retrospective study, the most significant predictor of bleeding was not the patient's platelet count but a history of bleeding in the prior 5 days. These data suggest that attention should be focused on providing aggressive platelet therapy for active bleeding rather than transfusing platelets prophylactically. Therapeutic platelet transfusions have been documented to control bleeding, and mortality rates are not increased when comparing patients receiving therapeutic to that seen in patients receiving prophylactic platelet transfusions.

Entities:  

Mesh:

Year:  2004        PMID: 15248165     DOI: 10.1016/j.tmrv.2004.03.003

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  55 in total

Review 1.  [Therapy with blood products].

Authors:  S Petros
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-01-29       Impact factor: 0.840

2.  Effects of Drug Concentration, Rate of Infusion, and Flush Volume on G-CSF Drug Loss When Administered Intravenously.

Authors:  Pirun Saelue; Warunsuda Sripakdee; Krit Suknuntha
Journal:  Hosp Pharm       Date:  2018-11-21

3.  2 Platelet Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  Blood component use and associated costs after standard dose chemotherapy--a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany.

Authors:  Bernadette Paessens; Angela Ihbe-Heffinger; Christoph von Schilling; Rita Shlaen; Rudolf Bernard; Christian Peschel; Wolfgang Schramm; Karin Berger
Journal:  Support Care Cancer       Date:  2011-05-12       Impact factor: 3.603

5.  Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.

Authors:  Asma Ashraf; Andreas V Hadjinicolaou; Carolyn Doree; Sally Hopewell; Marialena Trivella; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

6.  In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.

Authors:  Boris Shenkman; Yulia Einav; Tami Livnat; Ivan Budnik; Uriel Martinowitz
Journal:  Blood Transfus       Date:  2013-11-29       Impact factor: 3.443

7.  Bleeding frequency and characteristics among hematologic malignancy inpatient rehabilitation patients with severe thrombocytopenia.

Authors:  Jack B Fu; Jegy M Tennison; Isabel M Rutzen-Lopez; Julie K Silver; Shinichiro Morishita; Seyedeh S Dibaj; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2018-03-28       Impact factor: 3.603

8.  Evaluation of the Incidence of Ibuprofen Administration in Alcohol and Opioid Detoxification Patients With Concomitant Thrombocytopenia.

Authors:  Sheheryar Muhammad; John R Tomko; Laura M Wilson
Journal:  Hosp Pharm       Date:  2017-11-02

Review 9.  Platelets and Their Interactions with Other Immune Cells.

Authors:  Fong W Lam; K Vinod Vijayan; Rolando E Rumbaut
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

10.  Persistently elevated laboratory markers of thrombosis and fibrinolysis after clinical recovery in malaria points to residual and smouldering cellular damage.

Authors:  Anirban Dasgupta; Sandeep Rai; Amar Das Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2011-09-10       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.